Because vasodilatation may account for the flushing during an episode, the use of a vasoconstrictor seems reasonable. We hypothesized that midodrine, a vasoactive drug that causes vasoconstriction, might be effective. Midodrine, a peripherally acting α 1 -agonist, activates the α-adrenergic receptors of vessels, resulting in increased vascular tone and reduced blood volume. A patient with erythromelalgia responding to oral midodrine has been reported. 6 We used a topical preparation of midodrine for the management of erythromelalgia. We then reviewed reported outcomes among patients with erythromelalgia who received treatment with topically applied midodrine, 0.2%.
Methods | This study was conducted from November 1, 2011, to November 1, 2013, and was approved by the Mayo Clinic Institutional Review Board. Participants were patients in the Department of Dermatology at Mayo Clinic in Rochester, Minnesota, and provided written informed consent. The clinical diagnosis was erythromelalgia; midodrine, 0.2%, was to be applied topically, and patients were available for follow-up. Erythromelalgia was defined as the occurrence of red, hot, painful feet or hands. Midodrine, 0.2%, in a moisturizing skin cream (Vanicream) was compounded at the Mayo Clinic pharmacy and applied topically 3 times daily during symptoms.
After the diagnosis was confirmed, data were abstracted on demographics, adverse effects, and pain level before treatment. Using a verbal rating scale, the patient chose words to describe the sensory qualities of the pain and the overall experience of the pain. Each word chosen was assigned a rank value and these values were used to determine the pain rating index that ranges from 0 (no pain) to 5 (excruciating pain). Response to medication was graded as complete relief, substantial relief (≥50% relief or marked relief), some relief (<50% relief), no change, or worsening of symptoms. The grading scale was defined for the purposes of the study, and the data were derived from interpretation of descriptions in the medical record of how patients reported responding to midodrine, 0.2%.
Further information was obtained from documentation of follow-up visits to the department of dermatology after use of midodrine, 0.2%. Blood pressure was monitored in 2 patients before and after midodrine was prescribed.
Results | Topical midodrine, 0.2%, was prescribed for 12 patients with erythromelalgia (Table) . Most patients had received previously prescribed treatments with no substantial improvement. Of the 2 patients whose blood pressure was monitored before and after application of midodrine, 0.2%, prescription, 1 had no significant changes, but the other had an increase in blood pressure. Ten patients (83%) responded to therapy within minutes (not quantified).
Discussion | In this study, we summarized self-reported responses to a topical preparation of midodrine, 0.2%, that was used as needed. All but 1 patient reported improvement. Topical midodrine, 0.2%, was well tolerated; only 2 of the 12 patients (17%) reported adverse effects.
This study had limitations. The sample with available follow-up was small, available follow-up was documented in 
